Compounds and methods for scavenging dicarbonyl electrophiles
AssigneesVanderbilt University, The United States AS Represented By the Department of Veterans Affairs
InventorsKeith T. Wilson, John A. Oates, Olivier Boutaud, Venkataraman Amarnath, Erica J. Carrier, Alain P. Gobert
Life of this patent
Estimating the term…
Abstract
Compounds and methods of scavenging bifunctional electrophiles and reducing the occurrence of lysyl-levuglandin adducts in a subject in need thereof by administering a levuglandin adduct formation inhibiting amount of a compound of the following formula: wherein the variables are defined herein.
Claims19
A method of inhibiting the progression of a gastrointestinal cancer induced by a Helicobacter pylori infection immune response in a subject, comprising administering to the subject a levuglandin adduct formation inhibiting amount of a compound of the following formula:
- wherein:
- R1 is H, D, D2, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, carboxyl, substituted or unsubstituted aryl, or substituted or unsubstituted cycloalkyl;
- R2 is H, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, alkyl-alkoxy-R4;
- R3 is H, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, hydroxyl, nitro;
- R4 is H, D, D2, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, carboxyl, substituted or unsubstituted aryl, or substituted or unsubstituted cycloalkyl;
- R5 is H, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy;
- and pharmaceutical salts thereof.
A method of mitigating the progression of pre-malignant lesions induced by a Helicobacter pylori infection immune response in a subject in need thereof by administering an effective amount of a compound of the following formula:
- wherein:
- R1 is H, D, D2, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, carboxyl, substituted or unsubstituted aryl, or substituted or unsubstituted cycloalkyl;
- R2 is H, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, alkyl-alkoxy-R4;
- R3 is H, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, hydroxyl, nitro;
- R4 is H, D, D2, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, carboxyl, substituted or unsubstituted aryl, or substituted or unsubstituted cycloalkyl;
- R5 is H, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy;
- and pharmaceutical salts thereof.
A method of treating or inhibiting the progression of gastrointestinal carcinoma in a subject in need thereof, comprising administering an effective H. pylori infection reducing amount of a compound of the following formula:
- wherein:
- R1 is H, D, D2, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, carboxyl, substituted or unsubstituted aryl, or substituted or unsubstituted cycloalkyl;
- R2 is H, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, alkyl-alkoxy-R4;
- R3 is H, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, hydroxyl, nitro;
- R4 is H, D, D2, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, carboxyl, substituted or unsubstituted aryl, or substituted or unsubstituted cycloalkyl;
- R5 is H, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy;
- and pharmaceutical salts thereof.
Dependencies are inferred from the claim text.